초록접수 현황
| 20F-089 | 구연 발표 |
Intraoperative Thoracoscopic Identification of Thymic Masses Using Low-Dose Indocyanine Green
Yu Hua Quan 1,2, Rong Xu 1, Byeong Hyeon Choi 1,2, Jiyun Rho 1,2,, Beop-Min Kim3, Kook Nam Han 1, Young Ho Choi1, and Hyun Koo Kim 1,2,
1) Department of Thoracic and Cardiovascular Surgery, Korea University Guro Hospital
College of Medicine, Korea University, Seoul, Korea
2) Department of Biomedical Sciences, College of Medicine, Korea University, Seoul, Korea
3) Department of Bio-Convergence, Korea University, Seoul, Korea
Purpose : Thymic masses can be identified by intravenous injection of indocyanine green (ICG) during open surgery. However, consensus is lacking regarding the optimal ICG injection time and dose for thymic masses, and the use of ICG in robotic surgery or video-assisted thoracoscopic surgery (VATS) for thymic masses has not been reported. We aimed to evaluate the optimal ICG injection dose and timing for detecting thymic masses during robotic surgery or VATS.
Methods : Forty-nine consecutive patients diagnosed with thymic masses by preoperative computed tomography (CT) and scheduled to undergo thymic cystectomy or thymectomy were included. Thymic masses were observed during and after surgery using a near-infrared fluorescence imaging system, and analyzed fluorescent signal tumor-to-background ratio (TBR). Distribution of ICG in thymic masses was detected using a fluorescence microscope.
Results : There were no adverse effects related to systemic ICG injection and no cases involving major morbidity or mortality. The preoperative chest CT findings were correct in 27 (59%) of 49 cases. The TBR of the thymic cysts (0.4 ± 0.2) regardless of injection dose and time of ICG, and tumor size was significantly lower than that of the thymomas (3.2 ± 0.6) or thymic carcinomas (2.9 ± 0.5).TBR was not affected by injection time or injection dose of ICG, and tumor size and pathology.
Conclusion : In this study, we found that low-dose intravenous injection of ICG administered at flexible times before surgery enabled the accurate detection of thymic masses. This study’s findings can provide guidance for ICG-based VATS or robotic surgery of thymic masses
Methods : Forty-nine consecutive patients diagnosed with thymic masses by preoperative computed tomography (CT) and scheduled to undergo thymic cystectomy or thymectomy were included. Thymic masses were observed during and after surgery using a near-infrared fluorescence imaging system, and analyzed fluorescent signal tumor-to-background ratio (TBR). Distribution of ICG in thymic masses was detected using a fluorescence microscope.
Results : There were no adverse effects related to systemic ICG injection and no cases involving major morbidity or mortality. The preoperative chest CT findings were correct in 27 (59%) of 49 cases. The TBR of the thymic cysts (0.4 ± 0.2) regardless of injection dose and time of ICG, and tumor size was significantly lower than that of the thymomas (3.2 ± 0.6) or thymic carcinomas (2.9 ± 0.5).TBR was not affected by injection time or injection dose of ICG, and tumor size and pathology.
Conclusion : In this study, we found that low-dose intravenous injection of ICG administered at flexible times before surgery enabled the accurate detection of thymic masses. This study’s findings can provide guidance for ICG-based VATS or robotic surgery of thymic masses
책임저자: Hyun Koo Kim
Department of Thoracic and Cardiovascular Surgery, Korea University Guro Hospital College of Medicine
발표자: Yu Hua Quan, E-mail : hwa1983418@gmail.com